USP <1032> Design and Development of Biological Assays

USP General Chapter 〈1032〉 is an informational chapter on the design and development of biological assays (bioassays). It lays out scientific principles and good practices to build assays that yield analyzable, statistically sound dose–response data and are fit for their specific use, with particular emphasis on relative potency determinations because of the inherent variability of biological systems.

Scope and Concepts
The scope of 〈1032〉 is to guide the establishment and maintenance of bioassays that are fit for use across assay types (in vivo, ex vivo, and in vitro/cell-based). It focuses on relative-potency formats while noting that many principles generalize to other systems. The chapter complements 〈1033〉 (Biological Assay Validation) and 〈1034〉 (Analysis of Biological Assays).

Key Concepts and Principles

• Assay lifecycle perspective. 〈1032〉 centers on design and development and explicitly calls for ongoing monitoring of qualified assays using statistical process control (SPC) to detect trends (e.g., via control-charting system-suitability parameters). 〈1032〉 contributes to USP’s broader lifecycle framework (articulated in 〈1220〉), emphasizing design and monitoring as foundational elements.

• Fitness for use. Design decisions (e.g., linkage to mechanism of action, reagent qualification, matrix effects) should align with the assay’s intended purpose (lot release, stability, comparability, reference standard qualification, etc.). Performance needs (precision, relative accuracy, robustness) may differ by use.

• Dose–response modeling. Bioassays measure responses over concentration (dose) series for Standard and Test. 〈1032〉 discusses common parallel-response models and explicitly includes four-parameter (4PL) and five-parameter logistic functions (for symmetric/asymmetric sigmoids), as well as linear and polynomial options when justified. Concentrations are typically spaced geometrically (e.g., log scale).

• Relative potency & similarity (parallelism). Relative potency is estimated by comparing Test to a defined Standard under a model that assumes biological similarity. 〈1032〉 provides approaches for similarity/parallelism assessment, including parameter-based checks (e.g., asymptotes and slope for 4PL/5PL) and composite measures such as the parallelism sum of squares derived from residual sums of squares under parallel vs. separate fits, with equivalence-interval decision criteria derived from historical data. 〈1032〉 outlines the principle of assessing similarity/parallelism; detailed statistical methods are in 〈1034〉. USP explicitly discourages reliance on classical significance testing for parallelism, recommending equivalence-based approaches as more scientifically appropriate.

• System suitability ensures the model and assay perform as intended during a run; sample suitability verifies that the test article’s response is valid for potency estimation under the chosen model.

For compliance/regulatory purposes, it supports 〈1033〉 and 〈1034〉.